Optimising inhaled polymyxins as a vital therapy for pulmonary infections: A novel biochemical, molecular imaging and systems pharmacology approach

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1104581

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Lung infection is a leading cause of death in Australia and globally. Many bacterial pathogens are resistant to almost all current antibiotics. A class of ‘old’ antibiotics, polymyxins, are the last option for bacterial ‘superbugs’. Unfortunately, the current use of polymyxins is suboptimal and can cause severe kidney toxicity. This multi-disciplinary project will apply cutting-edge techniques to optimise inhaled polymyxin therapy for treatment of life-threatening pulmonary infections.

Funded Activity Details

Start Date: 01-01-2016

End Date: 01-01-2018

Funding Scheme: Project Grants

Funding Amount: $728,044.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Pharmacology and Pharmaceutical Sciences not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

antibiotic resistance | antibiotic therapy | molecular imaging | pharmacokinetics | transporters

Related Links